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2352-3042/Copyright ª 2014, ChongqiAbstract There have been significant advancements in the field of retinal gene therapy in
the past several years. In particular, therapeutic efficacy has been achieved in three separate
human clinical trials conducted to assess the ability of adeno-associated viruses (AAV) to treat
of a type of Leber’s congenital amaurosis caused by RPE65 mutations. However, despite the
success of retinal gene therapy with AAV, challenges remain for delivering large therapeutic
genes or genes requiring long DNA regulatory elements for controlling their expression. For
example, Stargardt’s disease, a form of juvenile macular degeneration, is caused by defects
in ABCA4, a gene that is too large to be packaged in AAV. Therefore, we investigated the ability
of helper dependent adenovirus (HD-Ad) to deliver genes to the retina as it has a much larger
transgene capacity.
Using an EGFP reporter, our results showed that HD-Ad can transduce the entire retinal
epithelium of a mouse using a dose of only 1  105 infectious units and maintain transgene
expression for at least 4 months. The results demonstrate that HD-Ad has the potential to
be an effective vector for the gene therapy of the retina.
Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. All
rights reserved.Introduction
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228 S. Lam et al.increases in visual function.1e3 Improvements in visual
perception compared to the baseline were still observed 1
year after treatment4 and immune response continued to
be minimal.5 The group with the largest cohort of 12 then
selected three patients for administration of the vector
into the contra-lateral eye that was not treated in the
initial trial. Both subjective visual function assessments and
objective measurements demonstrated improved visual
abilities in the newly treated eye and minimal immune
response.6 These data were very encouraging in the
development of retinal gene therapy as they demonstrated
the possibility of retinal gene therapy mediated by viral
vectors. The clinical trials also proved that the immune
response is minimal, likely due to the immune privileged
status of the eye.
However, the DNA carrying capacity of AAV is limited to
4.7 kb, and thus is not suitable for all applications. For
example, Stargardt’s disease is an autosomal recessive
form of juvenile macular degeneration caused by defects in
the gene ABCA4. Despite this contradiction, Allocca et al
has claimed success in expressing ABCA4 via AAV.7 However,
this finding was not commonly accepted and three indi-
vidual groups have followed up to find that the original
study likely observed an aberration of multiple, incomplete
parts of ABCA4 being carried by separate virions and that
co-transduction within the host cell led to random
recombination.8e10 As such, AAV cannot confer expression
of the ABCA4 protein to host cells. Although a lentiviral
vector has been shown to be capable of delivering the
ABCA4 gene to mouse photoreceptor cells,11 the insertion
of integration vectors is still a concern for human gene
therapy.12
The ABCA4 gene, with a CDS of 6.8 kb, encodes an ATP-
dependent flipase that is closely tied to phototransduction.
If this flipase is defective, its substrate, N-retinylidene-PE,
accumulates within the disc lumen. N-retinylidene-PE can
then react with a second molecule of all-trans retinal to
form di-retinoid-pyridinium-PE (A2PE). When the outer
segment of the PR cell is shed and phagocytosed by the
RPE, A2PE present in the segment’s disc lumen are also
taken up. Lysosomal degradation of this results in the hy-
drolytic product di-retinoid-pyridinium-ethanolamine
(A2E), which cannot be further degraded. Consequently,
A2E accumulates to form the lipofuscin deposits charac-
teristic of Stargardt’s disease, acting as a detergent that
compromises the membrane integrity,13,14 and converting
into free radical epoxides that are capable of killing the
retinal pigment epithelial (RPE) cells.15,16 With the loss of
the RPE, the corresponding PR cells lose the necessary
support required to sustain their function and cannot sur-
vive. As a result, a defect in ABCA4, a gene that functions in
the PR cells, results in the build-up of a toxic substrate that
does not affect the PR cells, but causes RPE apoptosis, thus
indirectly causing the death of the PR cells. This loss of the
PR cells is the mechanism by which Stargardt’s disease
causes a progressive retinal degeneration. Gene therapy
would bring clinical benefits to the patients if ABCA4 can be
effectively delivered to photoreceptor cells.
To examine vectors with a large DNA carrying capacity
for retinal gene delivery, our lab became interested in the
potential of using the helper-dependent adenoviral vector
(HD-Ad). With a packaging capacity ofw30 kb, it can carrysingle very large, or multiple small transgenes, along with
their associated promoters and other regulatory regions.
HD-Ad differs from traditional adenoviral vectors in that
the vector genome does not contain any viral coding se-
quences, but retains the inverted terminal repeats (ITR) for
DNA replication, and the viral packaging signal for encap-
sidation into viral particles. This allows for a larger payload
for gene delivery. In addition, the efficiency of transduction
is also increased, resulting in a higher number of cells
successfully transduced and increased transgene expression
for a given dose because the lack of viral genes equates
with a lack of viral proteins being produced within the
transduced cell. The presence of viral proteins would in-
crease the immune response to transduced cells and cause
them to be cleared by the immune system, hence reducing
the strength and duration of transgene expression.17 In
support of this, a previous study has shown that HD-Ad
vectors show reduced toxicity when delivered to mouse
lungs when compared with first generation adenoviral
vectors.18
In this study, we developed HD-Ad carrying the EGFP
reporter gene in expression cassettes under the control of
the ubiquitously expressed CAG promoter, or the combi-
nation of the rhodopsin and interphotoreceptor retinoid
binding protein enhancer (IRBPE) element to restrict
expression to photoreceptor cells. We then introduced
these vectors to mouse retinas via subretinal injection to
demonstrate the ability of HD-Ad to deliver transgenes to
the retina. Our results demonstrate that HD-Ad can trans-
duce the entire retinal pigment epithelium at very low
doses, with expression maintained for a minimum of 4
months.
Materials and methods
Cloning of the expression cassettes
EGFP from pEGFP-C1 was cloned into pBluescript II SK (þ)
by PCR and restriction digest using the forward primer (50-
ATCTGCAGCGCCACCATGGTGA-3), and the reverse primer
(5-ATGGATCCTCACTTGTACAGCTCGTCC-3), the latter of
which also inserted a stop codon. It was inserted using the
restriction sites PstI and BamHI.
The CAG promoter19 from a plasmid previously used in
our laboratory was cloned by restriction digest into this
plasmid to drive EGFP expression.
Separately, the rhodopsin promoter was cloned into the
same plasmid by PCR of the 1553 bp immediately upstream
of the start codon using the forward primer (5-GCATCTC-
GAGTGTTTGTGGTCCCTGTG-3), and the reverse primer (5-
GCATGATATCGGCTGTGGCCCTTG-3). The PCR template was
the Roswell Park Cancer Institute Human BAC Library RP11-
529F4 (The Center for Applied Genomics, Toronto). The
promoter was inserted using the restriction sites XhoI and
EcoRV. The IRBPE was then cloned into the rhodopsin pro-
moter carrying plasmid by PCR using the forward primer (5-
GCATGGTACCTGGAGGCAGAGGAGAAG-3), and the reverse
primer (5-GCATCTCGAGGCTTTATGAAGGCCAAAGA-3). It
was inserted using the restriction sites KpnI and XhoI.
The BGH poly-A sequence from pCDNA3 (Life Technolo-
gies Inc., Burlington) was cloned downstream of EGFP in
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cassette (PCAG-EGFP-polyA) and the Rho-EGFP expression
cassette (PRho-IRBPE-EGFP-polyA), both in pBluescript.
These cassettes were then transferred into pC4HSU20 for
HD-Ad production.
HD-Ad production
HD-Ad production took place using previously published
protocols.21,22 Briefly, the plasmids carrying the expression
cassettes in pC4HSU backbone were linearized to expose
the ITR and transfected into 116 cells. NG163 helper virus
was added to these cells and incubated to produce the HD-
Ad vector. The vector was released by lysing the cells by
repeated freezeethaw cycles. The lysate was then used to
co-infect 116 cells with helper virus, generating more HD-
Ad which were again released by lysing. This was
repeated several times with increasing cell culture sizes to
increase HD-Ad titer. The final production cycle was carried
out in 3 L suspension cultures and the HD-Ad was purified
from the lysate by CsCl gradient ultra-centrifugation. After
dialysis in 10 mM TriseHCl at pH 8.0, the purified HD-Ad was
quantified by measuring DNA content at OD260.
Flow cytometry
Cells in each well from a 24 well plate were trypsinized
using 200 mL of 0.25% trypsin with 2.21 mM EDTA. 800 mL of
PBS were then added to the well and the entire volume
transferred to a test tube and analyzed on a BD FACSCalibur
(BD Biosciences, Mississauga). Data analysis was performed
using FlowJo software (Tree Star Inc, Ashland).
Subretinal injection
All animal work described herein was performed at the
Laboratory Animal Services of the Hospital for Sick Children
with supervision by the veterinary staff and with the
approval of the Animal Care Committee. All animals were
mice of CD1 strain, and purchased through Charles River
Laboratories.
24 h before injection, the right eye of each mouse was
administered 1% atropine sulfate. Within 30 min of injec-
tion, 1% tropicamide and 2.5% phenylephrine HCl were
administered to the right eye, and readministered imme-
diately before injection if the pupil dilation was deemed
inadequate. The above ophthalmic solutions were pur-
chased from Alcon (Alcon Canada Inc., Mississauga). To
protect the eye and improve visualization into the eye, the
right eye was covered using a solution of 2.5% hypromellose
(Akorn, Lake Forest). For anesthesia, a mixture of 1 mg
ketamine and 0.1 mg xylazine per 10 g body weight was
administered by intraperitoneal injection. These were
sourced from Zoetis (Zoetis Canada, Kirkland) and Bayer
(Bayer HealthCare, Toronto) respectively.
All injections took place when the mice were 3e6 weeks
of age. Before injection, fluorescein (SigmaeAldrich Can-
ada Ltd., Oakville) was added to a final concentration of
0.1 mg/mL to give color to the vector suspension such that
the injection could be better visualized.The subretinal injection was done in a trans-corneal
manner as described by Timmers et al.23 The plunger was
then depressed at a rate of less than 1 mL/min. After the
plunger had been fully depressed, the needle was held in
place for an additional 60 s. After the needle had been
withdrawn, a small amount of Cortimyxin antibiotic oint-
ment (Sandoz Canada, Boucherville) was applied.
Sectioning and confocal microscopy
After enucleation, the eyes were fixed in 4% para-
formaldehyde in PBS and incubated for 2 h. After fixation,
the eye was dissected. The cornea was cut away using
straight 2 mm Vannas spring scissors (Fine Science Tools
Inc., North Vancouver). The lens was then extracted slowly
using forceps and the remaining tissue was washed 3 times
with PBS for 5 min each, and an increasing concentration of
sucrose up to 20% w/v in 5% steps with 15 min between each
step at room temperature. After embedding in freezing
medium, the blocks were cut into 12 mm thick sections.
For confocal microscopy, a Nikon A1R Si point scanning
confocal microscope was used. To obtain high resolution
while covering the large area of an entire mouse eye, each
image consists of many individual confocal images, stitched
together by software to form a single image. Before scan-
ning the large image, each section was mapped for location
and a focus map formed to compensate for leveling. Up to
120 images (10  12 fields) were then acquired by the
acquisition software Nikon NIS Elements, and stitched with
15% overlap. After acquisition and stitching, image manip-
ulation was performed using Volocity 6.1 (PerkinElmer Inc,
Woodbridge).
Results
Analysis of promoter preference and transduction
efficiency in cultured cells
To determine the infectious unit titer and to confirm cell-
specificity of the Rho-EGFP construct, ARPE-19 and WERI-Rb
cells transduced with either CAG-EGFP or Rho-EGFP car-
rying HD-Ad were analyzed by flow cytometry in order to
obtain a quantitative comparison as shown in Fig. 1. ARPE-
19, a retinal pigment epithelium derived cell line, was used
as an analog of the retinal pigment epithelium while WERI-
RB, a retinoblastoma derived cell line, was used to for its
ability to express genes restricted to photoreceptor cells.
Both cell types produced EGFP when transduced with CAG-
EGFP. However, when transduced with Rho-EGFP, only
WERI-Rb yielded fluorescence, while there was absolutely
no EGFP production from Rho-EGFP transduced ARPE-19
cells despite the high doses applied. This indicates that
the combination of rhodopsin promoter and IRBPE has suf-
ficient cell-specificity. These results are reflected both in
the percentage of positively gated cells (Fig. 1A) as well as
mean fluorescence intensity. (Fig. 1B and C).
To determine the infectious titer of vector particles, we
extrapolated the number of VP/cell that yields 50% trans-
duction by curve fitting. The curve-fit function applied was
Y Z Bmax$X/(Kd þ X ) where X Z VP/cell; Y Z percentage
positive cells; Bmax Z binding maximum (assumed to be
Fig. 1 Flow cytometry results of cultured cells transduced with CAG-EGFP or Rho-EGFP HD-Ad. Flow cytometry indicates that (A)
the percentage of positively gated cells increased in dose dependent manner when either cell type was transduced with CAG-EGFP.
WERI-Rb but not ARPE-19 responded to Rho-EGFP. (B, C) Similar results were obtained when examining the mean fluorescence
intensity with increases observed with dose in all cases except for when ARPE-19 was transduced with Rho-EGFP, again confirming
the cell-specificity of Rho-EGFP. Statistical analyses to compare the percentage of positive cells were not performed as they were
clearly dose dependent, as were the mean fluorescence intensities. Curve fit for the percentage of positively gated cells for ARPE-
19 and WERI-Rb after transduction with CAG-EGFP (D) is used for determining the infectious titer. The results reveal that 1 in 133
vector particle is capable of conferring transgene expression. (The numbers following CAG/Rho indicate VP/cell applied. 3 days
post-transduction. n Z 3. Error bars represent standard error of the mean. 2-way ANOVA of the CAG promoter (B) found statis-
tically significant difference on dose only while 2-way ANOVA of the Rho promoter found statistically significant interaction be-
tween dose and cell-type. Pairwise comparisons were not conducted).
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required to achieve 50% binding) (Fig. 1D).
The R2 value for the curve fit for ARPE-19 and WERI-Rb
cells were 0.9316 and 0.9082 respectively. The Kd was
calculated to be 92.40 (77.84e107.0, 95% CI) for ARPE-19
and 230.1 (191.7e268.4, 95% CI) for WERI-Rb cells, both
transduced with CAG-EGFP. These values correspond with
the number of vector particles per cell (VP/cell) required
to transduce 50% of the cells. The difference between cell
lines is indicative of the differences in the ability of each
cell-type to be transduced (i.e. transduction efficiency). As
ARPE-19 demonstrated a 2.5 fold higher transduction effi-
ciency than WERI-Rb, the calculations below were based on
a Kd of 92.40 from ARPE-19. In other words, 92.4 VP/cell is
required to infect 50% of the cells.
As defined by the Poisson distribution, the multiplicity of
infection required to infect 50% of the cells is ln(0.5) or
0.693. Since 92.4 VP/cell transduced 50% of the cells, a
conservative estimate of the number of active vector par-
ticles per total number of vector particles was calculated to
be approximately 92.4/0.69 or 133. In other words, 1 in 133
VP was infectious. It is likely that the actual ratio of in-
fectious particles per vector particle was even higher as
there were multiple assumptions and simplificationsinvolved and that transduction of ARPE-19 did not occur at
100% efficiency. Therefore, we estimated that approxi-
mately 1 in 100 vector particles was infectious in our
transduction experiments.CAG-EGFP confers expression of EGFP throughout
the entire retinal epithelium using only 1 3 105 IU
and can be maintained for at least 4 months
Having confirmed the in vitro function of the vectors, we
injected the vector into the subretinal space of mice to
determine whether the vectors transduce mouse retinas
efficiently. Fig. 2 demonstrates the typical results of CAG-
EGFP injection with 1  108 IU. 10 separate sections were
taken approximately 100 mm apart, progressing from the
inferior to the superior side of the eye. It is clear from this
set of images that the RPE has been completely transduced
across all three dimensions. A high magnification view
(Fig. 3) demonstrates that all cells in the RPE exhibited
fluorescence.
Given the complete transduction of the retinal epithe-
lium, 10 serial dilutions of the vector were injected to
determine the lowest dose required to establish complete
Fig. 2 Fluorescence images of sequential sections throughout a CAG-EGFP HD-Ad injected eye. Sequential sections of CAG-EGFP
injected mouse eyes reveal that the RPE was transduced across the entire retina. The sections are 12 mm each, separated by
approximately 100 mm. The sections are in the transverse plane, progressing from the inferior to the superior side. The eye was
injected with 1  108 IU in 1 mL of HDAd carrying CAG-EGFP. The animal was sacrificed 1 week post-injection. (Scale
bar Z 500 mm).
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232 S. Lam et al.epithelial transduction (Fig. 4A). The results show that
significant amounts of fluorescence can be detected using
as little as 1  103 IU, and complete epithelial transduction
can be assured at 1  105 IU.
Having determined the minimal dose for reliable com-
plete epithelial transduction, this dose was used to deter-
mine the maximum duration of long term transgene
expression (Fig. 4B). The results demonstrate that strong
EGFP can be observed for a minimum of 4 months, the
longest time-point planned in the experiment.Expression is largely limited to the RPE, but there
are patches of neural-retinal transduction
The results presented thus far show that transduction
across the retina was robust, but was only observed in
the RPE as was observed in the vast majority of cases.
However, in approximately 20% of the CAG-EGFP injected
eyes, cells in the neural retina could be observed to give
a strong fluorescent signal. This had been observed in
large patches of cells covering up to 20% of the
retina (Fig. 5). There is no obviously discernible pattern
of where these patches occur as they are random in
location and not localized to the injection site nor any
anatomical feature.Fig. 3 High magnification confocal photomicrograph of a
CAG-EGFP HD-Ad injected retina. A high magnification view of
the retina after injection with CAG-EGFP reveals that the
fluorescence was exclusive to the RPE layer, indicating that the
vector did not transduce the photoreceptor cells. (RPE e
retinal pigment epithelium; OS e outer segment (photorecep-
tors); ONL e outer nuclear layer; INL e inner nuclear layer;
1  108 IU in 1 mL of HDAd encoding CAG-EGFP; 1 week post-
injection; Scale bar Z 50 mm).Injections of Rho-EGFP results in sporadic, limited
transduction restricted to photoreceptor cells
In order to assess the photoreceptor specificity of the Rho-
EGFP construct in vivo, HD-Ad vector carrying the construct
was injected into the subretinal space using methods
identical to CAG-EGFP injections. In the majority of cases,
no transduction could be detected in the retina (Fig. 6A).
However, in approximately 20% of the cases, small areas of
transduction can be found (Fig. 6B and D). Under high
magnification, it is apparent that in these areas, fluores-
cence is restricted exclusively to the photoreceptor cells
(Fig. 6C and E). These areas of transduction indicate that
the rhodopsin promoter construct confers cell-specific
transgene expression. This is consistent with the complete
lack of transduction of the RPE, including in areas where
successful photoreceptor transduction can be found.
Discussion
Adenoviral gene therapy has been in development for many
decades, and this study was not the first in attempting to
apply adenoviral gene therapy for the treatment of retinal
disease. However, it is the first to demonstrate the high
efficacy with which HD-Ad can transduce the retinal
epithelium at very low doses, and prove that strict cell
specificity can be obtained using transcriptional regulation.
We have also identified challenges to the in vivo application
of the vector that have not been previously encountered in
the transduction of the neural retina.
Potential application of HD-Ad in RPE diseases
While large area views of the retina show the complete
transduction of the RPE across the entire retina, the high
magnification views demonstrate that all of the cells of the
RPE are successfully transduced with no visible breaks in
the transduction. However, these high magnification views
also demonstrate that there is no transduction in cell types
other than the RPE.
The titer of the vector was determined in this study via
flow cytometry of transduced cultured cells. Earlier ver-
sions of adenoviral vectors can replicate in a permissible
cell line, thus a precise titer based on plaque forming units
(PFU) can be determined. However, as HD-Ad lacking all
viral genes, the titer must be determined by expression of
transgenes after transduction. We chose to determine the
infectious unit (IU) titer by flow cytometry because it
avoids inaccuracies associated with counting individual
cells during a limiting dilution assay, as well as accounting
for multiple simultaneously transduced cells by employing
the Poisson distribution. This yields a more accurate
quantitation of vector activity than using either viral par-
ticle (VP) titer or by limiting dilution assays.
Previous dosage studies with first-generation (E1 dele-
tion only) adenoviral vectors in mice have shown that
1  107 PFU is the minimum required to obtain complete
RPE transduction carrying a CMV-LacZ expression
cassette.24 Other studies have subsequently used this dose
as an absolute minimum, often with doses as high as 1  109
PFU and have repeatedly demonstrated that doses under
Fig. 4 Fluorescence photomicrographs of retinas injected with very low doses of CAG-EGFP HD-Ad after 1, 2 and 4 months. (A)
Injections of low doses of CAG-EGFP reveal that the fluorescence is detectable in the RPE across the entire retina at 1  105 IU but
became more sparse with lower doses. (B) Long-term monitoring of mice injected with 1  105 IU of CAG-EGFP indicates that strong
transgene expression can be detected for a minimum of 4 months in the majority of the retinal epithelium. (A: All doses at 1 mL of
HDAd encoding CAG-EGFP; 1 week post-injection; b: 1  105 IU in 1 mL of HDAd encoding CAG-EGFP; both: Scale bar Z 500 mm).
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Our data clearly demonstrates that complete transduction
can be obtained at a dose of 1  105 IU or lower. The high
magnification examination of these injected retinas reveals
that there are no breaks or untransduced areas across the
entire retinal epithelium at these low doses.
A lower viral vector titer naturally lends itself to lower
toxicity and combined with the lower toxicity inherent in
HD-Ad, offers a tantalizing possibility for retinal gene
therapy targeting the RPE given our ability to transduce
the entire retinal epithelium at very low doses. Of the
many causes of inherited retinopathies, the RPE-specific
genes that have been recognized so far are RPE65, LRAT,27
MERTK28 and RDH5.29 Of these four genes, only MERTK is
not directly involved in the visual cycle. RPE65 has been
well studied and is well into human clinical trials using
AAV.1,2,4e6,30 LRAT gene therapy has been studied with
significant electro-physiological results but poor distribu-
tion of gene expression.31 Furthermore, it has been argued
that the regulatory regions required for LRAT expressioncannot be packaged using the AAV vector.27 MERTK has
been treated in animal studies using lentivirus,32 adeno-
virus,33 as well as AAV.34,35 A human clinical trial using AAV
has been initiated but the results are as yet unpublished.28
A lessor known disease is also caused by mutations in
RDH5, a retinal-pigment epithelial specific gene that can
cause retinal degeneration with no known treatment.29
Due to its low prevalence, treatment for this disease has
not been well studied. All such RPE specific diseases could
potentially be treated with helper-dependent adenoviral
vectors, especially given that the distribution and
expression levels observed in this study are
unprecedented.Patches of complete retinal transduction
In the majority of injection of vectors carrying CAG-EGFP,
no transduction of the neural retina could be observed
while the entirety of the RPE was fluorescent. However, in
Fig. 5 High magnification confocal photomicrograph of a
patch of complete retinal transduction in a CAG-EGFP HD-Ad
injected retina. Confocal microscopy of CAG-EGFP injected
mice reveal that occasional transduction of cells other than the
RPE can be observed. These can occur as patches where many
cell-types are transduced across the retinal layers. (RPE e
retinal pigment epithelium; OS e outer segment (photorecep-
tors); ONL e outer nuclear layer; INL e inner nuclear layer;
1  105 IU in 1 mL of HDAd encoding CAG-EGFP; 1 week post-
injection; Scale bar Z 100 mm).
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retina could be observed. Similarly, injections of vectors
carrying Rho-EGFP displayed no fluorescence in the ma-
jority of cases, although occasional patches of fluorescence
limited to the photoreceptor cells could be observed.
Because the location of these patches varies, it is
apparent that the patches do not correspond to any
particular anatomical feature in the eye. They are also not
localized to the injection site as the patches can occur near
the edge of the retina while the injection is targeted to-
wards the center of the retina. However, although these
patches do not correspond to the injection site, it is
nonetheless possible that they arise from injection injury.
Specifically, as the use of a dissection microscope gave only
limited depth perception and the physical resistance pro-
vided by the eye is minimal, it is possible that the needle
tip had scraped and damaged the retina in those areas
unintentionally. This indicates that HD-Ad is able to trans-
duce the photoreceptor cells. If we consider the possibility
that these patches indicate areas where there was inad-
vertent injury to the retina, the logical explanation would
be that the lack of transduction in other cases represents
an inability to access and/or infect the cells, while the
physical injury imparted provided a route of infection to
the neural retina.
It is possible that the trauma caused a release of cyto-
kines that resulted in the movement of receptors and/or
co-receptors to become accessible on the surface of the
target cells, making the cells susceptible to transduction.
This is supported by evidence from adenoviral infection of
the respiratory tract.36 In that study, it was shown that the
release of cytokines from infected macrophages causes the
migration of integrins to the apical surface of cultured
polarized epithelial cells, giving opportunity for adenovirus
to infect the epithelium. It is possible that the retinal injurycauses a similar release in cytokines, resulting in changes in
the neural retinal cells to become susceptible to infection
or transduction.
It is also possible that the barrier to infection is physical.
The neural retina is sandwiched by two limiting mem-
branes; the inner limiting membrane that is in contact with
the vitreous, and the outer limiting faces the subretinal
space and the RPE. The outer limiting membrane forms a
barrier between Mu¨ller cells and photoreceptor inner seg-
ments, leaving the outer segments exposed to the sub-
retinal space. From the complete transduction of the RPE,
we can surmise that there is a very large number of vector
particles present in the subretinal space between the RPE
and the outer limiting membrane. The presence of these
patches of transduced cells indicates that the vector is
capable of transducing the neural retina, including photo-
receptor cells. Therefore, the most logical explanation is
that the vector is unable to transduce photoreceptor cells
by entering via the photoreceptor cell segments. Rather,
the vector must be exposed to the cell-body in the outer
nuclear layer in order to establish transduction. Meanwhile,
the barrier formed by the outer limiting membrane results
in the inability of the HD-Ad vector to travel into the outer
nuclear layer. For future study, we propose the injection of
a-aminoadipic acid (AAA) with the vector. AAA has been
documented as a method by which the outer limiting
membrane can be disrupted to allow for increased inte-
gration of transplanted stem cell precursors from the sub-
retinal space.37 Therefore, the injection of AAA before or
during the injection of the vector would allow for the
transient, reversible disruption of the outer limiting mem-
brane, thus providing access for the vector to transduce the
photoreceptors.38
In summary, it is clear from the results that helper-
dependent adenoviral vectors are highly effective for
delivering genes to the RPE at a very low dose, resulting in
prolonged expression lasting for a minimum of 4 months.
However, it is disappointing that effective, widespread
transduction of the neural retina could not be achieved
using our methods. Based on the presence of the patches of
transduction observed, there appears to be an issue with
access to the relevant cells by the vector rather than the
ability of the vector to transduce such cells. With modifi-
cations to the method of delivery of the vector, such as pre-
treating the retina with AAA, it may be possible to trans-
duce the neural retina. The results with Rho-EGFP vector
have shown that if a method of delivery could be found to
introduce the vector to the neural retina, the IRBP
enhancer e rhodopsin promoter construct is capable of
limiting gene expression to only the photoreceptors.
Moving forward in the application of helper-dependent
adenoviral vectors in retinal gene therapy, the focus should
shift towards the use of this unique vector to deliver genes
to the RPE as the results herein has proven it to be highly
effective with long duration of transgene expression at very
low doses. If a method of delivery can be developed for
introducing the vector to the neural retina, it would also
unlock HD-Ad vectors for transduction of photoreceptor
cells. It would allow for the delivery of large genes to the
cells of the neural retina to treat diseases that involve
genes too large to be packaged in AAV. Such progress in the
study of HD-Ad would give hope to the patients of a variety
Fig. 6 Low and high magnification confocal photomicrographs of Rho-EGFP HD-Ad injected retinas. Injections of Rho-EGFP
usually resulted in no visible transduction (A). However, in approximately 20% of the cases, areas of transduction can be found
(B and D; each from different mice; areas of transduction are highlighted with dashed red lines). High magnification views of these
areas reveal that transduction is exclusive to photoreceptor cells (C and E, corresponding to the red boxed area of B and D
respectively). (RPE e retinal pigment epithelium; OS e outer segment (photoreceptors); ONL e outer nuclear layer; INL e inner
nuclear layer; Scale barsZ 500 mm (A, B, D), Scale barsZ 100 mm (C and E); 1  108 IU in 1 mL of HDAd vector carrying Rho-EGFP; 1
week post-injection).
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ease, for whom there is no present cure.
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